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In this issue and in a recent issue of Cell, Vahedi et al. and Samstein et al. provide new insights into
the strategies used to establish an enhancer landscape during development of cell lineages. They
report that enhancer landscapes characterizing T cell lineages are pre-established and strongly
influenced by environmental stimuli.Transcription in eukaryotes is regulated
by sequence-specific DNA-binding pro-
teins associated with a gene’s promoter,
which encompasses the transcription
start site, and also by one or more distant
control regions, including enhancers.
Enhancers typically bind several DNA-
binding proteins and coregulatory pro-
teins that modulate chromatin structure
and directly communicate with the tran-
scription machinery positioned at the
promoter. Until recently, our knowledge
was based on studies of only a small
number of model enhancers because
enhancers were difficult to identify at a
genome-wide scale. During the past few
years, postgenomic technologies have re-
vealed characteristic features of poised
and active enhancers that have facilitated
enhancer discovery. By taking advantage
of this newfound capability, Vahedi et al.
(2012) and Samstein et al. (2012) in this
issue and in a recent issue of Cell have
expanded our knowledge of the diverse
strategies used to activate enhancersduring the development of mammalian
cell lineages.
Vahedi et al. (2012) focused on
active enhancers in two subtypes of
mature helper T cells—Th1 and Th2
cells—which, in a simplistic view, pro-
mote immune responses to intracellular
and extracellular microbial pathogens, re-
spectively. These two cell types develop
from the same naive Th cell precursor
upon T cell receptor (TCR) engagement
in the presence of different cytokine
signals. Th1 development is catalyzed
by IL-12 and IFN-g, which activate the
STAT4 and STAT1 transcription factors,
respectively. Among themany genes acti-
vated by these STAT proteins in the naive
Th cell is Tbx21, which encodes the T-bet
transcription factor that is considered to
be a master regulator of Th1 develop-
ment. In contrast, Th2 development is
catalyzed by IL-4, which activates the
STAT6 transcription factor that cooper-
ates with the Th2-specifying factor,
GATA3.To identify enhancers that are active in
mature Th1 and Th2 cells, Vahedi et al.
(2012) performed chromatin immunopre-
cipitation sequencing (ChIP-seq) analysis
for the transcriptional coactivator and
histone acetyltransferase, p300. The sig-
nificance of p300 association is thought
to be distinct from that of another promi-
nent enhancer mark, monomethylation
of histone H3 at lysine 4 (H3K4me1).
H3K4me1 is thought to mark both active
enhancers and inactive enhancers that
are poised for activation, whereas p300
is more closely associated with active
enhancers (Heintzman et al., 2007; Visel
et al., 2009; Ghisletti et al., 2010).
The first surprise to emerge from this
analysis was that a high percentage of
p300-marked regions (excluding pro-
moter regions) differed between the
closely related Th1 and Th2 populations;
45% and 35% of p300 peaks were
unique to Th1 or Th2 cells, respectively.
Remarkably, extending the analysis to
macrophages and embryonic stem cellsovember 21, 2012 ª2012 Elsevier Inc. 929
Figure 1. Signal-Dependent and Lineage-Specific Regulators Cooperate on a Pre-existing Enhancer Landscape
(Left) Signal-dependent and lineage-specific transcription factors (TFs) act on pre-existing enhancers previously established by other lineage-specifying
regulators, such as pioneer TFs. Binding of signal-dependent TFs, such as STAT1 and STAT4 proteins in Th1 cells, promotes recruitment of the transcriptional
coactivator p300 and correlates with cell-type-specific gene activation. (Right) Binding of signal-dependent TFs to pre-existing lineage-inappropriate enhancers,
such as enhancers associated with alternative cell fates, leads to dissociation of p300 and transcriptional repression.revealed virtually no overlap in p300
peaks. One possible explanation for the
vastly different p300 profiles is that p300
may not associate with the enhancers of
broadly expressed genes, such as house-
keeping genes. Consistent with this
possibility, the authors were unable to
find p300 peaks in the vicinity of a collec-
tion of broadly expressed genes. It
remains to be determined whether the
paucity of p300 peaks in the vicinity of
these genes is because their enhancers
generally function in a p300-independent
manner, which is consistent with recent
evidence of p300-independent enhancers
(Krebs et al., 2011), or because many
broadly expressed genes may not be re-
gulated by enhancers at all. As mentioned
above, most early studies focused on
enhancers for tissue- or developmental-
stage-specific genes, raising the possi-
bility that much of the current dogma
about enhancer function does not extend
to all genes.
The second unexpected result
emerged when Vahedi et al. (2012) exam-
ined the transcription factor requirements
for p300 and H3K4me1 marking of the
Th1- and Th2-specific enhancers. Pre-
vious studies had revealed that the
marking of lineage-specific enhancers is
dictated by key regulators of lineage
specification (Ghisletti et al., 2010; Heinz930 Cell 151, November 21, 2012 ª2012 Elseet al., 2010; Mercer et al., 2011). For
example, PU.1, E2A, EBF, and other regu-
lators of B cell development regulate the
deposition of the H3K4me1 mark at
many B-cell-specific enhancers, whereas
PU.1 collaborates with C/EBP proteins at
macrophage-specific enhancers (Heinz
et al., 2010). In addition to promoting
deposition of H3K4me1, these factors
promote nucleosome remodeling and
confer susceptibility to activation by envi-
ronmental stimuli. For example, microbial
stimulation of mature macrophages
results in the activation of NF-kB, which
associates with a subset of the enhancers
that had been marked by H3K4me1 at an
early stage of macrophage development;
NF-kB binding promotes enhancer acti-
vation, at least in part, through the recruit-
ment of p300 (Ghisletti et al., 2010). The
preferential binding of environmentally
induced factors to enhancers previously
marked by lineage-specifying factors
has also been observed in other cell types
(Mullen et al., 2011; Trompouki et al.,
2011).
On the basis of these earlier studies,
one might have expected that the Th1
specification factor, T-bet, would serve
as a primary regulator of the enhancer
landscape in Th1 cells by promoting
H3K4me1 deposition and p300 re-
cruitment. However, the p300- andvier Inc.H3K4me1-marked enhancer landscape
was relatively unaltered when cells from
T-bet-deficient (Tbx21/) micewere acti-
vated under Th1-promoting conditions.
Instead, p300 recruitment to a large
percentage of enhancers was dependent
on the STAT4 and STAT1 proteins that
respond to the cytokine microenviron-
ment and mediate cytokine responses in
a broad range of cell types. Importantly,
H3K4me1 deposition at the Th1-specific
enhancers appeared to precede the
Th1-Th2 lineage decision. These results
suggest that the STAT proteins promote
the activation (as defined by p300 recruit-
ment) of a subset of enhancers that had
become poised for activation at an earlier
stage of T cell development (Figure 1, left).
Interestingly, binding of STAT proteins led
to loss of p300 engagement at another
subset of enhancers, including enhancers
associated with alternative cell lineages
(Figure 1, right), suggesting that STATs
may exert both positive and negative
effects on enhancer signatures depend-
ing on the chromatin context. The mecha-
nism by which T-bet contributes to the
Th1 cell fate decision is less certain,
although the authors noted a stronger
correlation between T-bet binding and
transcriptional repression than transcrip-
tional activation. Analogous to the Th1
results, p300 binding to Th2-specific
enhancers was found to be more strongly
dependent on the cytokine-induced
factor STAT6 than on the lineage-speci-
fying factor, GATA3.
Data presented in the recent study of
Samstein et al. (2012) are consistent with
the view that lineage-specifying transcrip-
tion factors can function primarily by
taking advantage of an enhancer land-
scape established by other transcription
factors. This study focused on T regula-
tory (Treg) cells, which can either develop
in the thymus from hematopoietic progen-
itors or in the periphery from naive T cells
as an alternative to the Th1 and Th2 fates.
Specification of the Treg lineage relies in
the transcription factor FoxP3, which is
both necessary and sufficient for Treg
development. To determine how FoxP3
regulates Treg development, Samstein
et al. (2012) compared the properties of
promoters and enhancers in FoxP3+
Treg cells and in FoxP3 Treg progeni-
tors. However, rather than examining
p300 and H3K4me1, the authors per-
formed genome-wide analyses of DNase
I hypersensitivity. Genomic regions at
which nucleosomes have been exten-
sively remodeled or evicted become
hypersensitive to DNase I digestion, and
nucleosome remodeling/eviction gener-
ally correlates with enhancer and pro-
moter activity.
Samstein et al. (2012) found very few
differences in the DNase hypersensitivity
profile in FoxP3+ and FoxP3 cells.
Furthermore, FoxP3 binding was ob-
served primarily at regions that exhibited
hypersensitivity prior to FoxP3 expres-
sion. Most of these sites exhibited hyper-
sensitivity prior to TCR engagement,
which is consistent with the view that
much of the enhancer landscape was
established at an early stage of T lineage
development. However, a subset became
hypersensitive following TCR engage-
ment but before FoxP3 expression, impli-
cating factors induced by TCR signaling,such as AP-1 and NFAT, in the nucleo-
some remodeling events that promote
DNase hypersensitivity.
Strikingly, despite the use of different
experimental methods, the two stud-
ies support a similar model in which tran-
scription factors that have long been
known to play critical roles in lineage
specification, in particular T-bet and
FoxP3, do not appear to play major roles
in establishing the enhancer landscape
that characterizes the lineages they regu-
late. Because the Th1, Th2, and Treg line-
ages involve the late differentiation of cells
that already are fully committed to the
T cell lineage, it is tempting to speculate
that reliance on an enhancer landscape
established at an earlier stage of develop-
ment or in response to the environment
will be unique to factors that act at
late developmental stages. However,
because early cell fate decisions can
also be influenced by environmental
stimuli and because tissue-specific en-
hancers can be marked in pluripotent
embryonic stem cells, it remains possible
that a subset of the factors that are critical
for early cell fate decisions will also rely on
a pre-established enhancer landscape.
One clear goal for the future will be to
better understand the precise roles of
factors like FoxP3 and T-bet in lineage
specification. The current data suggest
that FoxP3 may simply bind and activate
a subset of enhancers within the avail-
able landscape, thereby promoting Treg
development. In contrast, T-bet may act
through different mechanisms, given the
stronger association of T-bet binding
with genes downregulated during Th1
development. Of broader relevance,
improved tools for identifying functional
enhancers and assigning them to their
target genes and also for distinguishing
functionally relevant transcription factor
binding sites from those that may result
from opportunistic interactions will be
needed to more fully evaluate largeCell 151, Ngenomic data sets. These technological
advances would help reveal whether cell
fate decisions are strongly dependent on
the thousands of enhancers and binding
sites for specification factors identified
by using current technologies or whether
the functional burden is carried by a rela-
tively small subset of enhancers and inter-
action sites whose properties would then
be of primary importance for future mech-
anistic studies.REFERENCES
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